AKT1 and Parkinson disease: According to the docking results, it is speculated that YGJ may act on CCND1, EGFR, ERBB2, MAP2K1, MAPK1, MTOR, and VEGFA targets to modulate PI3K-Akt signaling pathway, thereby treating PD by affecting the peripheral system.